Apeloa Pharmaceutical welcomed Michael Stanek to join the company as a CDMO.

Apeloa is a pharmaceutical company founded in 1989, headquartered in Zhejiang as a member of Hengdian Group. With over 7,000 employees, Apeloa ranks as China's top 2 API exporter and among the top 5 CDMO companies. We offer integrated services across API, CDMO, FDF, and ACI, with branches in Shanghai, Boston, Frankfurt and Tokyo. Our products span cardiovascular, anti-infection, psychotropic, and anti-cancer treatments. Apeloa’s sites are certified by global regulators, including NMPA, FDA, EDQM, EMEA, PMDA and KFDA. We have strategic partnerships with leading global pharmaceutical companies, providing end-to-end CDMO services that advance customer molecules to market. Our mission is to use technology for health. Apeloa invests over 5% of revenue annually into R&D, focus on technology-driven innovation and cost efficiency. Our dedicated team of 1,300+ scientists collaborates with top universities to deliver high-quality, affordable medicines worldwide, dedicated to be a global leading technology-driven pharmaceutical manufacturer.

Founded 1989